The Investigation of the Mechanism of Cachexia Occurrence for Patients With Gastrointestinal Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04594863

Enrollment

100

Registered

2020-10-20

Start date

2020-11-01

Completion date

2021-06-01

Last updated

2020-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cachexia

Brief summary

The study is going to recruit patients with gastrointestinal cancer, collect clinical data and peripheral blood sample and possible fat samples. The expression of SIRT-6 in peripheral blood will be tested and connect with different status of cachexia of the patients. A mathematical model of the relationship between cachexia classification and SIRT-6 expression is going to constructed as anticipated.

Detailed description

At the start of cancer develop, not all patients with gastrointestinal cancer manifest cachexia, it may be associated with SIRT-6 expression. This study will collect and test the peripheral blood sample of patients, use it as an important indicator of the degree of cachexia, and provide references for clinical drug intervention, prognosis and dietary intervention for cachexia patients. If possible, fat sample of the patients will be collected during surgery, and the adipose progenitor cells will be cultured to find the key target proteins by detecting differences in protein expression, changes in protein modification levels, and protein interactions.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

1. Age between 18 and 90 years old, unlimited gender; 2. Patients who are diagnosed with gastrointestinal cancer for the first time and are planning to undergo further treatment; 3. Volunteer to participate and sign the informed consent form.

Exclusion criteria

1. Women who are pregnant or lactate; 2. Patients with severe metabolic diseases; combined with cardiac function, liver and kidney dysfunction, acute myocardial infarction and acute stroke in the past 3 months , COPD acute onset respiratory failure and other serious medical diseases and patients who need hormone therapy

Design outcomes

Primary

Measure	Time frame	Description
SIRT-6 expression	4 months	SIRT-6 expression tested by ELISA

Countries

China

Contacts

Primary ContactKang Yu, MD

yuk1997@sina.com+8613801130457

Backup ContactFang Wang

yours.fang@hotmail.com+8615201646084

Outcome results